BAY 41-8543 and BAY 73-6691

sGC stimulator combined with PDE9 inhibitor attenuated renal fibrosis in 5/6 nephrectomized rats by down-regulating fibrosis-related gene expression. This novel approach of using low-dose combination therapies to minimize side effects while maintaining therapeutic efficacy offers a promising strategy for the treatment of CKD. It highlights the critical role of changes in gene transcription as an early marker of treatment effectiveness.